v3.25.4

Common Stock Reverse Split (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2025 | Dec. 31, 2024
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE | The following table sets forth the computation of the basic and diluted net loss per share: SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE
|  | September 30, 2025 |  |  | September 30, 2024 |  |  | September 30, 2025 |  |  | September 30, 2024 |
|  | Three months ended |  |  | Nine months ended |
|  | September 30, 2025 |  |  | September 30, 2024 |  |  | September 30, 2025 |  |  | September 30, 2024 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (4,459,764 | ) |  | $ | (10,092,312 | ) |  | $ | (11,973,902 | ) |  | $ | (14,185,887 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding |  |  | 8,367,774 |  |  |  | 4,517,125 |  |  |  | 6,673,074 |  |  |  | 4,169,490 |
Net loss per share, basic and diluted |  | $ | (0.53 | ) |  | $ | (2.23 | ) |  | $ | (1.79 | ) |  | $ | (3.40 | )
| The following table sets forth the computation of the basic and diluted net loss per share: SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE
|  | Year ended December 31, 2024 |  |  | Period from March 16, 2023 (inception) through December 31, 2023 |
Numerator: |  |  |  |  |  |  |  |
Net loss |  | $ | (23,753,863 | ) |  | $ | (3,793,585 | )
Denominator: |  |  |  |  |  |  |  |
Weighted average shares outstanding |  |  | 4,282,194 |  |  |  | 4,039,651 |
Net loss per share, basic and diluted |  | $ | (5.5 | ) |  | $ | (0.90 | )
SCHEDULE OF ANTI-DILUTIVE EFFECT | The following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have had an anti-dilutive effect: SCHEDULE OF ANTI-DILUTIVE EFFECT
|  | September 30, 2025 |  |  | September 30, 2024 |
Unvested common stock – restricted shares (Note 5) |  |  | - |  |  |  | 12,541 |
Restricted Stock options |  |  | 31,377 |  |  |  | 85,166 |
Restricted Stock Units |  |  | 151,701 |  |  |  | 328,191 |
Performance Stock units |  |  | 50,658 |  |  |  | 50,658 |
Sponsor Earnout Shares (Note 4)* |  |  | - |  |  |  | - |
Public warrants |  |  | 486,413 |  |  |  | 486,413 |
Private warrants |  |  | 556,666 |  |  |  | 556,666 |
Inducement warrants |  |  | 958,400 |  |  |  | - |
Short term loan warrants |  |  | 86,591 |  |  |  | - |
Private placement warrants |  |  | 6,425 |  |  |  | - |
Potentially dilutive shares |  |  | 958,400 |  |  |  | - |
* | The Sponsor Earnout Shares (as defined in the Business Combination Agreement) were not included for purposes of calculating the number of diluted shares outstanding as of September 30, 2025, as the Sponsor Earnout Shares remain contingently forfeitable, as the conditions have not been met.
| The following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have had an anti-dilutive effect: SCHEDULE OF ANTI-DILUTIVE EFFECT
|  | December 31, 2024 |  |  | December 31, 2023 |
Unvested common stock – restricted shares (Note 8) |  |  | 6,270 |  |  |  | 164,050 |
Restricted stock options |  |  | 70,999 |  |  |  | - |
Restricted stock units |  |  | 248,640 |  |  |  | - |
Performance stock units |  |  | 50,659 |  |  |  | - |
Sponsor earnout shares (Note 3)* |  |  | - |  |  |  | - |
Public warrants |  |  | 4,864,133 |  |  |  | - |
Private placement warrants |  |  | 5,566,667 |  |  |  | - |
* |  | The Sponsor Earnout Shares (as defined in the Business Combination Agreement) were not included for purposes of calculating the number of diluted shares outstanding as of December 31, 2024, as the Sponsor earnout shares remain contingently forfeitable, as the conditions have not been met
SCHEDULE OF ASSUMPTIONS UNDER THE MONTE CARLO MODEL |  | The Earnout Shares were valued using the following assumptions under the Monte Carlo Model that assumes optimal exercise of the Company’s redemption option at the earliest possible date: SCHEDULE OF ASSUMPTIONS UNDER THE MONTE CARLO MODEL
Market price of public stock |  | $ | 97.4 |
Expected term (years) |  |  | 8 years |
Volatility |  |  | 60.00 | %
Risk-free interest rate |  |  | 4.25 | %
Dividend rate |  |  | 0.00 | %
Sponsor [Member] |  |
SCHEDULE OF ASSUMPTIONS UNDER THE MONTE CARLO MODEL | The Sponsor Earnout Shares were valued using the following assumptions under the Monte Carlo Model that assumes optimal exercise of the Company’s redemption option at the earliest possible date: SCHEDULE OF ASSUMPTIONS UNDER THE MONTE CARLO MODEL
|  | March 31, 2025 |  |  | December 31, 2024 |
Market price of public stock |  | $ | 4.716 |  |  | $ | 35.8 |
Expected term (years) |  |  | 7.27 years |  |  |  | 7.52 years |
Volatility |  |  | 75.00 | % |  |  | 65.00 | %
Risk-free interest rate |  |  | 4.10 | % |  |  | 4.50 | %
Dividend rate |  |  | 0.00 | % |  |  | 0.00 | %

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_TitleOfIndividualAxis=SDST_SponsorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |